Postbariatric Hypoglycemia Clinical Trial
Official title:
A Phase 1 Single and Multiple Ascending Dose and Drug Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts. Part A involves a single dose of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part B involves repeat doses of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part C involves the evaluation of rosuvastatin and acetaminophen pharmacokinetics in the presence and absence of MBX 1416.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05541939 -
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
|
Phase 2 | |
Completed |
NCT03373435 -
Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
|
Phase 2 | |
Active, not recruiting |
NCT05721729 -
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
|
Phase 2 |